Key highlights from the Type C FDA meeting include: FDA confirms the approach that the proposed primary endpoint of the ...
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results